MA27837A1 - Beta-carbolines utiles pour traiter une maladie inflammatoire. - Google Patents

Beta-carbolines utiles pour traiter une maladie inflammatoire.

Info

Publication number
MA27837A1
MA27837A1 MA28592A MA28592A MA27837A1 MA 27837 A1 MA27837 A1 MA 27837A1 MA 28592 A MA28592 A MA 28592A MA 28592 A MA28592 A MA 28592A MA 27837 A1 MA27837 A1 MA 27837A1
Authority
MA
Morocco
Prior art keywords
inflammatory disease
treating inflammatory
useful
beta carbolines
beta
Prior art date
Application number
MA28592A
Other languages
English (en)
French (fr)
Inventor
Michael E Hepperle
Julie Fields Liu
Francois Soucy
Yingchun Ye
Robert S Murray
Raman Prakash
Jeremy D Little
Alfredo Castro
Hormoz Mazdiyasni
Paul E Fleming
Dominic Reynolds
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA27837A1 publication Critical patent/MA27837A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA28592A 2003-04-09 2005-11-09 Beta-carbolines utiles pour traiter une maladie inflammatoire. MA27837A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09

Publications (1)

Publication Number Publication Date
MA27837A1 true MA27837A1 (fr) 2006-04-03

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28592A MA27837A1 (fr) 2003-04-09 2005-11-09 Beta-carbolines utiles pour traiter une maladie inflammatoire.

Country Status (22)

Country Link
US (2) US7727985B2 (https=)
EP (1) EP1611134A1 (https=)
JP (1) JP2006522824A (https=)
KR (1) KR20060006031A (https=)
CN (1) CN1802375A (https=)
AU (1) AU2004230952A1 (https=)
BR (1) BRPI0409263A (https=)
CA (1) CA2521300A1 (https=)
CO (1) CO5700746A2 (https=)
CR (1) CR8042A (https=)
EA (1) EA009121B1 (https=)
EC (1) ECSP056145A (https=)
HR (1) HRP20050926A2 (https=)
MA (1) MA27837A1 (https=)
MX (1) MXPA05010793A (https=)
NI (1) NI200500174A (https=)
NO (1) NO20054598L (https=)
OA (1) OA13115A (https=)
RS (1) RS20050832A (https=)
TN (1) TNSN05257A1 (https=)
WO (1) WO2004092167A1 (https=)
ZA (1) ZA200508198B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409263A (pt) 2003-04-09 2006-03-28 Millennium Pharm Inc composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
BRPI0509660A (pt) * 2004-04-09 2007-10-09 Millennium Pharm Inc compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5249772B2 (ja) * 2005-11-22 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション キナーゼの阻害剤として有用な三環式化合物
EP2001455A2 (en) 2006-03-15 2008-12-17 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
EP2125841A1 (en) * 2006-12-13 2009-12-02 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
US20090131422A1 (en) * 2007-10-23 2009-05-21 Millennium Pharmaceuticals, Inc. Salts of an IKK inhibitor
US20090137579A1 (en) * 2007-10-23 2009-05-28 Millennium Pharmaceuticals, Inc. Mesylate salt of an IKK inhibitor
US20110111417A1 (en) 2008-05-14 2011-05-12 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
EP2366699B1 (en) 2008-10-02 2013-08-07 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
KR101461767B1 (ko) 2010-03-30 2014-11-13 노파르티스 아게 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
CN103596949A (zh) * 2011-03-28 2014-02-19 Sjt分子研究有限公司 用于代谢综合征的治疗的化合物
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2242402T3 (es) * 1998-08-12 2005-11-01 Pfizer Products Inc. Inhibidores de tace.
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
HK1054039B (zh) * 2000-03-15 2010-04-16 萨诺费－阿文蒂斯德国有限公司 取代的β-咔啉
EP1268477B1 (en) * 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
US9248124B2 (en) * 2001-11-07 2016-02-02 Millennium Pharmaceuticals, Inc. Use of inhibitors of IκB kinase for the treatment of cancer
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0409263A (pt) 2003-04-09 2006-03-28 Millennium Pharm Inc composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita

Also Published As

Publication number Publication date
TNSN05257A1 (en) 2007-07-10
OA13115A (en) 2006-11-10
WO2004092167A8 (en) 2006-01-05
NO20054598L (no) 2005-10-27
EA009121B1 (ru) 2007-10-26
EA200501584A1 (ru) 2006-06-30
BRPI0409263A (pt) 2006-03-28
ECSP056145A (es) 2006-04-19
AU2004230952A1 (en) 2004-10-28
CR8042A (es) 2006-05-30
EP1611134A1 (en) 2006-01-04
CO5700746A2 (es) 2006-11-30
CN1802375A (zh) 2006-07-12
JP2006522824A (ja) 2006-10-05
KR20060006031A (ko) 2006-01-18
WO2004092167A1 (en) 2004-10-28
US20040235839A1 (en) 2004-11-25
RS20050832A (sr) 2007-12-31
HRP20050926A2 (en) 2006-06-30
CA2521300A1 (en) 2004-10-28
US20100093713A1 (en) 2010-04-15
MXPA05010793A (es) 2005-12-05
NO20054598D0 (no) 2005-10-06
NI200500174A (es) 2006-04-17
ZA200508198B (en) 2007-01-31
US7727985B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
MA27837A1 (fr) Beta-carbolines utiles pour traiter une maladie inflammatoire.
NL1028304A1 (nl) Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
DE602004019373D1 (de) Bilderzeugungsverfahren
NO20053860D0 (no) COP 1 for behandling av inflammatorisk tarmsykdom.
EP1941908A4 (en) THERAPEUTIC AGENT AGAINST HEART DISEASES
DE602005010597D1 (de) Bildaufzeichnungsverfahren
IL178328A0 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
ZA200707498B (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
IL180721A0 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
ITRE20030089A1 (it) Gruppo autocentrante perfezionato.
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
EP1844158A4 (en) BIOMARKER FOR INFLAMMATORY ENDURANCE
EP2212321A4 (en) (1,4-DIAZABICYCLO [3.2.2] NON-6-EN-4-YL) HETEROCYCLYLMETHANONE LIGANDS FOR NICOTINE ACETYLCHOLIN RECEPTORS SUITABLE FOR THE TREATMENT OF DISEASES
EP1546308A4 (en) METHOD FOR TREATING AUTOIMMUNE DISEASE
EP1593378A4 (en) MEDICINE FOR THE TREATMENT OF VIRUS DISEASES
EP2044957A4 (en) AGENT FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
EP1536000A4 (en) Method of judging inflammatory disease
EP1974732A4 (en) THERAPEUTIC AGENT AGAINST NEURODE GENERATIVE DISEASES
LU91032B1 (de) Mauerstein.
FR2858344B1 (fr) Bloc pour paroi bio climatique.
FI20030467A0 (fi) Menetelmä tulehdustilojen hoitamiseen
ITVI20060251A1 (it) Gruppo perfezionato per l'egorazione di acqua miscelata.
LU91028B1 (fr) Brique améliorée.
HK1090917A (en) Beta-carbolines useful for treating inflammatory disease
FR2858212B1 (fr) Cercueil en particulier pour la cremation